François Riglet

François Riglet

Auto-generated profile, based on publicly available information

François Riglet

Servier R&D Institute Paris Saclay Gif‐sur‐Yvette France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
FRFrançois Riglet
François Riglet
FMFrance Mentre
France Mentre
CVChristine Veyrat-Follet
Christine Veyrat-Follet
JBJulie Bertrand
Julie Bertrand

6 October 2020 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
FRFrançois Riglet
François Riglet
JBJulie Bertrand
Julie Bertrand
ABAurélie Barrail-Tran
Aurélie Barrail-Tran
CVCéline Verstuyft
Céline Verstuyft
HMHugues Michelon
Hugues Michelon
CBCaroline Barau
Caroline Barau
Background and Objective Mycophenolate mofetil is widely used in kidney transplant recipients. Mycophenolate mofetil is hydrolysed by blood esterases to mycophenolic acid (MPA), the active drug. Although MPA therapeutic drug monitoring has been recommended to optimise the treatment efficacy by the area under the plasma concentration vs time curve, little is known regarding MPA concentrations in peripheral blood mononuclear cells, where MPA inhibits inosine monophosphate dehydrogenase. This study aimed to build a pharmacokinetic model using a population approach to describe MPA total and unbound concentrations in plasma and into peripheral blood mononuclear cells in 78 adult kidney transplant recipients receiving mycophenolate mofetil therapy combined with tacrolimus and prednisone. Methods Total and unbound plasma concentrations and peripheral blood mononuclear cell concentrations were assayed. A three-compartment model, two for plasma MPA and one for peripheral blood mononuclear cell MPA, with a zero-order absorption and a first-order elimination was used to describe the data. Results Mycophenolic acid average concentrations in peripheral blood mononuclear cells were well above half-maximal effective concentration for inosine monophosphate dehydrogenase and no relationship was found with the occurrence of graft rejection. Three covariates affected unbound and intracellular MPA pharmacokinetics: creatinine clearance, which has an effect on unbound MPA clearance, human serum albumin, which influences fraction unbound MPA and the ABCB1 3435 C>T (rs1045642) genetic polymorphism, which has an effect on MPA efflux transport from peripheral blood mononuclear cells. Conclusion This population pharmacokinetic model demonstrated the intracellular accumulation of MPA, the efflux of MPA out of the cells being dependent on P-glycoprotein transporters. Nevertheless, further studies are warranted to investigate the relevance of MPA concentrations in peripheral blood mononuclear cells to dosing regimen optimisation.

17 June 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
CBChloe Burlot
Chloe Burlot
FRFrançois Riglet
François Riglet
MRMathilde Romagnoli
Mathilde Romagnoli
ALAriane Leconte
Ariane Leconte
ADAudrey Delmas
Audrey Delmas
SFSylvain Fouliard
Sylvain Fouliard
This work aims to assess the S65487‐induced disruption of the B‐cell lymphoma‐2 (Bcl2)/Bcl2‐like protein 11 (Bim) complex at therapeutic doses via a pharmacokinetic/pharmacodynamic model and to reconcile pharmacokinetic data from microdoses and therapeutic doses in a single population pharmacokinetic model. The first model consists of a linear 3‐compartment pharmacokinetic model linked to an indirect response model with concentration‐dependent inhibition of Bcl2/Bim complex formation. Simulations predicted a 97.6% maximum reduction in complex formation with 1200 mg of S65487, following a sustained administration schedule and using characteristics from phase I/II patients. Before clinical trials were conducted in cancer patients, a microdose study was conducted in healthy volunteers. Although S65487 exhibited slightly nonlinear pharmacokinetics at therapeutic doses, pharmacokinetic parameters estimated after microdose administration differed substantially. Thus, several hypotheses were explored to reconcile the microdose and therapeutic data within a unified PK model. Nonlinearity in drug disposition emerged as the most biologically plausible explanation. A Michaelis–Menten approximation of the target‐mediated drug disposition model was applied to elimination and distribution processes to estimate parameters through saturable pathways. Performance of this second model, the microdose optimized pharmacokinetic model, was evaluated by comparing population predicted and observed area under the curve. This optimized model demonstrated significant improvement, reducing the difference in the description of exposure for the microdose study from 5‐ to 1‐fold, without compromising the description at therapeutic doses. This modified model has a wider range of applicability across doses and could support the extrapolation of microdose study results to therapeutic doses in future research.